Empagliflozin Vs Dapagliflozin in Type 2 Diabetes Patients Inadequately Controlled with Metformin, Glimepiride & Dipeptidyl Peptide 4 Inhibitors

Diabetes Research and Clinical Practice
10 Apr, 2019 ,

Eu Jeong Ku et al assessed the efficacy and safety of two distinct sodium-glucose cotransporter 2 (SGLT2) inhibitors, empagliflozin vs dapagliflozin, as part of a quadruple oral antidiabetic agents (OADs) regimen. This investigation was conducted in T2D subjects with glycated hemoglobin (HbA1c) from 7.5-12.0% with metformin, glimepiride, and dipeptidyl peptidase-4 inhibitors. For this open-labeled, prospective, 52-week study, patients received either empagliflozin (25 mg/day) or dapagliflozin (10 mg/day). In T2D patients who are treated with three other OADs, SGLT2 inhibitors could be effectively used as a fourth OAD. More specifically, in reducing HbA1c and improving other cardiometabolic parameters, empagliflozin was more effective than dapagliflozin.


Full content



To directly compare the effectiveness and safety between two distinct sodium-glucose co-transporter 2 (SGLT2) inhibitors, empagliflozin and dapagliflozin, as part of a quadruple oral antidiabetic agents (OADs) in patients with inadequately controlled type 2 diabetes (T2D).


This study was an open-labeled, prospective, 52-week study conducted in T2D patients with glycated hemoglobin (HbA1c) ranging 7.5–12.0% with metformin, glimepiride and dipeptidyl peptidase-4 inhibitors. Patients were divided into either empagliflozin (25 mg/day) or dapagliflozin (10 mg/day). The outcome measures included changes in HbA1c, fasting plasma glucose (FPG), and cardiometabolic variables and the safety profiles.


In total, 350 patients were enrolled with empagliflozin (n = 176) and dapagliflozin (n = 174), respectively. After 52 weeks, both groups showed significant reductions in HbA1c and FPG, but the reduction was greater in the empagliflozin group (P < 0.001). Both groups showed significantly decreased blood pressure and body weight and high-density lipoprotein cholesterol levels were increased in the empagliflozin (between groups, P = 0.035). Both groups showed similar safety profiles.


Our study demonstrated that SGLT2 inhibitors can be effectively used as a fourth OAD in T2D patients who are treated with three other OADs. More specifically, empagliflozin was more effective in reducing HbA1c and improving other cardiometabolic parameters than dapagliflozin.